ArticleAnnals of hematology2026
Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast hematopoietic neoplasms (BHN) are rare and may either primarily (PBHN) or secondarily (SBHN) involve breast tissue. The widespread use of needle biopsy for diagnosis of breast lesions necessitates knowledge of their presentation, radiologic aspects, histomorphology, and outcomes for seeking appropriate hematopathology consultation. Herein, we present our clinical experience as an academic institution and referral center of BHN in the past 20 years. We identified 59 patients diagnosed at the University of Chicago Medical Center between 2002-2021. Demographic, pathologic, radiologic, therapy, relapse data, and vital status were abstracted. Data were examined using univariable statistics with event-free and overall survival (EFS, OS) as primary outcomes examined with the lymphoma subgroup using Cox PH regression adjusted for age. The cases included 27 (46%) PBHN and 32 (54%) SBHN in a cohort comprising 93% females, mostly white (56%). The mean age at diagnosis was 58.8 years. Lymphomas were the most frequent BHN (86.4% of all cases). Patients with primary breast lymphomas (PBL) were significantly older than those with secondary breast lymphomas (SBL) (61.2 vs. 49.8 yrs, p<0.02). The most frequent lymphomas were extranodal marginal zone lymphoma (MZL) (32.2%) and diffuse large B-cell lymphoma/high grade B-cell lymphoma, not otherwise specified (DLBCL/HGBCL, NOS) (33.9%). Over half of MZLs and DLBCLs were primary in the breast. Within B-cell lymphomas, 20 (37%) were high grade with inferior 10-yr overall survival (OS) (age-adjusted HR 5.47, 95% CI 1.38, 21.64) compared to low-grade without any impact on event free survival (EFS). This is one of the largest cohorts so far describing BHN. DLBCL and MZL remain the most common lymphomas involving this site. Most patients were diagnosed via core needle biopsy (CNB) and did not have a prior BHN. Radiographically, the presentation may closely mimic breast carcinoma. FDG PET is a mainstay in the diagnosis and management of BHN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.